|Day's Range||285.02 - 296.95|
|52 Week Range||244.28 - 333.65|
|PE Ratio (TTM)||18.51|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
After a solid second quarter, management lays out plans for future growth.
Coming off its successful launch of Spinraza, the first drug approved to treat children and adults with spinal muscular atrophy (SMA), Biogen Inc (NASDAQ:BIIB) released second quarter revenues yesterday. Tecfidera, Rituxan and Gazyva, Avonex and Plegridy all outclassed consensus, while Plegridy and Tysabri fell in line with the Street.
Yesterday, shares of Biogen (BIIB) finished lower on the day despite the fact that it reported Street-beating earnings. Today, they're gaining what they should have yesterday after Goldman Sachs upgraded ...